NCT04513704View on ClinicalTrials.gov

A Clinical Trial Comparing Semaglutide in Healthy People Who Eat and Take the Medicine at Different Times

PHASE1CompletedINTERVENTIONAL
Enrollment

156

Participants

Timeline

Start Date

August 28, 2020

Primary Completion Date

April 20, 2021

Study Completion Date

May 26, 2021

Conditions
Healthy Volunteers Type 2 Diabetes
Interventions
DRUG

Oral Semaglutide

Participants will receive oral semaglutide tablet once daily for 10 days (3 mg for first 5 days and 7 mg for the next 5 days).

Trial Locations (1)

HA1 3UJ

Novo Nordisk Investigational Site, Harrow

Sponsors

Lead Sponsor

Novo Nordisk A/S
All Listed Sponsors
lead

Novo Nordisk A/S

INDUSTRY

NCT04513704 - A Clinical Trial Comparing Semaglutide in Healthy People Who Eat and Take the Medicine at Different Times | Biotech Hunter | Biotech Hunter